Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer.
Volume: 37, Issue: 15_suppl, Pages: e16530 - e16530
Published: May 20, 2019
Abstract
e16530 Background: Changes in PSA are widely used as a biomarker for the monitoring of treatment outcome in Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the clinical real-world setting. Early PSA changes (before 12 weeks) are not considered in the definition of PSA Progression (PSAProg) due to the potential for spurious “flare” reactions. We aimed to evaluate the significance of an early PSA increase in Abiraterone/Enzalutamide...
Paper Details
Title
Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer.
Published Date
May 20, 2019
Journal
Volume
37
Issue
15_suppl
Pages
e16530 - e16530
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History